Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
amgen
3
×
boston blog main
clinical trials
inclisiran
3
×
life sciences
national blog main
new york
new york blog main
new york top stories
pcsk9 inhibitors
3
×
regeneron pharmaceuticals
alirocumab
biotech
boston top stories
evolocumab
national top stories
rna interference
cholesterol
deals
drugs
evercore isi
fda
heart attack
joseph swartz
medicines co.
novartis
pcsk9
praluent
repatha
sanofi
stroke
svb leerink
the medicines co.
the medicines company
umer raffat
What
cholesterol
drug
medco
3
×
medicines
fda
lowering
new
acquire
agreed
alnylam
based
billion
bringing
brings
cash
clears
closer
company
compound
data
deal
evidence
filing
heart
inched
lasting
long
looms
market
morning
novartis
partner
pharmaceuticals
phase
poised
positive
preps
presented
ready
reckoning
Language
unset
Current search:
medco
×
amgen
×
" pcsk9 inhibitors "
×
inclisiran
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms